Letter comments on: Glomerular filtration rate estimation for carboplatin dosing in patients with gynaecological cancers

Autor: Cartwright, D., White, M., Crearie, C., Forte, C., Coulter, S., Brown, J., Randhawa, M., Glasspool, R., Roxburgh, P.

Publikováno v: In ESMO Open August 2022 7(4)

Real-world effectiveness of systemic anticancer therapy for advanced melanoma in the west of Scotland from 2010 to 2018.

Autor: Clarke J; NHS Greater Glasgow & Clyde, Glasgow, G12 0XH, Scotland.; Strathclyde Institute of Pharmacy & Biomedical Sciences, University of Strathclyde, Glasgow, G4 0RE, Scotland., Bennie M; Strathclyde Institute of Pharmacy & Biomedical Sciences, University of Strathclyde, Glasgow, G4 0RE, Scotland.; Public Health Scotland, Edinburgh, EH12 9EB, Scotland., Kurdi A; Strathclyde Institute of Pharmacy & Biomedical Sciences, University of Strathclyde, Glasgow, G4 0RE, Scotland.; Department of Pharmacology & Toxicology, College of Pharmacy, Hawler Medical University, Erbil, Iraq., Pan J; Department of Mathematics & Statistics, University of Strathclyde, Glasgow, G1 1XH, Scotland., Mueller T; Strathclyde Institute of Pharmacy & Biomedical Sciences, University of Strathclyde, Glasgow, G4 0RE, Scotland., Crearie C; NHS Greater Glasgow & Clyde, Glasgow, G12 0XH, Scotland., Baillie K; NHS Greater Glasgow & Clyde, Glasgow, G12 0XH, Scotland., Laskey J; NHS Greater Glasgow & Clyde, Glasgow, G12 0XH, Scotland., Waterston A; NHS Greater Glasgow & Clyde, Glasgow, G12 0XH, Scotland.

Publikováno v: Future oncology (London, England) [Future Oncol] 2023 Feb; Vol. 19 (6), pp. 451-461. Date of Electronic Publication: 2023 Apr 11.

Correction to: The impact of COVID-19 on systemic anticancer treatment delivery in Scotland.

Autor: Baxter MA; Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK.; Tayside Cancer Centre, Ninewells Hospital and Medical School, NHS Tayside, Dundee, UK., Murphy J; NHS Lanarkshire, South Lanarkshire, UK., Cameron D; Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, UK.; Edinburgh Cancer Centre, NHS Lothian, Edinburgh, UK., Jordan J; NHS Grampian, Aberdeen, UK., Crearie C; West of Scotland Cancer Network, Glasgow, UK., Lilley C; Edinburgh Cancer Centre, NHS Lothian, Edinburgh, UK., Sadozye A; West of Scotland Cancer Network, Glasgow, UK., Maclean M; West of Scotland Cancer Network, Glasgow, UK., Hall P; Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, UK.; Edinburgh Cancer Centre, NHS Lothian, Edinburgh, UK., Phillips A; Tayside Cancer Centre, Ninewells Hospital and Medical School, NHS Tayside, Dundee, UK., Greger A; NHS Grampian, Aberdeen, UK., Madeleine J; NHS Highland, Inverness, UK., Petty RD; Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK. r.petty@dundee.ac.uk.; Tayside Cancer Centre, Ninewells Hospital and Medical School, NHS Tayside, Dundee, UK. r.petty@dundee.ac.uk.

Publikováno v: British journal of cancer [Br J Cancer] 2021 May; Vol. 124 (10), pp. 1745.

Use of record linkage to evaluate treatment outcomes and trial eligibility in a real-world metastatic prostate cancer population in Scotland.

Autor: Baillie K; Beatson West of Scotland Cancer Centre, NHS Greater Glasgow & Clyde, Glasgow, UK., Mueller T; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK., Pan J; Department of Mathematics and Statistics, University of Strathclyde, Glasgow, UK., Laskey J; Beatson West of Scotland Cancer Centre, NHS Greater Glasgow & Clyde, Glasgow, UK., Bennie M; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.; Public Health Intelligence, NHS National Services Scotland, Edinburgh, UK., Crearie C; Beatson West of Scotland Cancer Centre, NHS Greater Glasgow & Clyde, Glasgow, UK., Kavanagh K; Department of Mathematics and Statistics, University of Strathclyde, Glasgow, UK., Alvarez-Madrazo S; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK., Morrison D; Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK., Clarke J; Beatson West of Scotland Cancer Centre, NHS Greater Glasgow & Clyde, Glasgow, UK., Keel A; Innovative Healthcare Delivery Programme (IHDP), University of Edinburgh, Edinburgh, UK., Cameron D; Cancer Research UK Edinburgh Centre, University of Edinburgh, Edinburgh, UK., Wu O; Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK., Kurdi A; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK., Jones RJ; Beatson West of Scotland Cancer Centre, NHS Greater Glasgow & Clyde, Glasgow, UK.; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.

Publikováno v: Pharmacoepidemiology and drug safety [Pharmacoepidemiol Drug Saf] 2020 Jun; Vol. 29 (6), pp. 653-663. Date of Electronic Publication: 2020 Apr 21.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.